Non-Moderated Poster Abstract
Eposter Presentation
https://storage.unitedwebnetwork.com/files/1237/c282c3dde3be88fb5e285e4ef5bbc43b.pdf
Accept format: PDF. The file size should not be more than 5MB
https://storage.unitedwebnetwork.com/files/1237/be636043203801d47d3ec768c1950449.jpg
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
The association of ADAM-10 gene polymorphisms and clinical characteristics of urothelial carcinoma
Non-Moderated Poster Abstract
Basic Research
Oncology: Bladder and UTUC
Author's Information
3
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Taiwan
Shian Shiang Wang sswdoc@vghtc.gov.tw Taichung Veterans General hospital Department of Urology Taichung Taiwan *
Jian Ri Li fisherfishli@yahoo.com.tw Taichung Veterans General Hospital Department of Urology Taichung Taiwan -
Shun Fa Yang ysf@csmu.edu.tw Chung Shan Medical University Institute of Medicine Taichung Taiwan -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
Urothelial cell carcinoma (UCC) is a common cancer in the world and is one of the leading causes of cancer death. UCC commonly occurs in the renal pelvis, ureter and bladder. In the past, many studies have showed that integrin-like metalloproteinases (A Disintegrin and metalloproteinase; ADAM) is a class of secreted proteolytic enzymes. ADAM and matrix metalloproteinases (Matrix metalloproteinases; MMPs) have similar extracellular matrix hydrolysis function and are widely involved in cancer formation. In addition, many studies demonstrate that ADAM-10 has a relatively high expression in cancer tissues and is positively correlated with the prognosis and survival of patients. ADAM-10 does play an important role in the carcinogenic process of certain tissues in the literature. However, the mechanism and genetic polymorphism of ADAM-10 and the correlation between UCC have been rarely discussed.
In this study, we analyze the gene expressions from 719 urothelial carcinoma patients via real-time genotype PCR to evaluate the polymorphism of rs653765, rs2305421 and rs514049 in ADAM-10 genes, and to investigate the correlation with the clinical manifestations such as tumor grade and TNM stage of UCC.
The results of this study showed that among 719 patients with UCC, there was no significant correlation between patients with ADAM-10 rs653765 gene polymorphisms and clinical tumor stage, tumor size, lymph node metastasis, distant metastasis, and histopathological grade. However, patients with rs2305421 AG and GG in ADAM-10 genes have a higher risk of large tumor. In addition, we have also observed that patients with polymorphisms of ADAM-10 rs514049 AC and CC genes have a higher risk of muscle invasive UCC.
In conclusion, the polymorphisms of the rs2305421 in ADAM-10 gene with G allele is associated with the tumor size of UCC, while the patients with ADAM-10 rs514049 AC and CC genotypes have higher risk of muscle invasive cancer. The polymorphisms of the ADAM-10 rs2305421 and rs514049 genes can be regarded as a relevant factor for the clinical manifestations of UCC.
ADAM-10, urothelial carcinoma, single‐nucleotide polymorphism
 
 
 
 
 
 
 
 
 
 
1723
 
Presentation Details
 
 
 
0